Molecular dissection of cyclosporin A's neuroprotective effect reveals potential therapeutics for ischemic brain injury

Brain Sciences

Volumn 3, Issue 3, 2013, Pages 1325-1356

  Kawakami, Minoru ^a  

^a FISHERIES RESEARCH AGENCY   (Japan)

Author keywords

Cyclosporin a; Ischemic cell death; Neuroprotective agent; Transcriptional regulation

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ALBUMIN; ANTIOXIDANT; ARUNDIC ACID; AX 200; CITICOLINE; CLOMETHIAZOLE; CYCLOSPORIN A; DISUFENTON SODIUM; E 2051; EBSELEN; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; GAVESTINEL; GLUTAMIC ACID; GM 1; GRANULOCYTE COLONY STIMULATING FACTOR; LUBELUZOLE; MAGNESIUM; MONOSIALOGANGLIOSIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALMEFENE; NEUROPROTECTIVE AGENT; NICARAVEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMODIPINE; NORPHENAZONE; ONO 2231; PICLOZOTAN; PIRACETAM; PRAMIPEXOLE; S 15176; STAT3 PROTEIN; SUN N 4057; SUN N 8075; TACROLIMUS; TIRILAZAD; TS 011; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANGIOGENESIS; BLOOD CLOT LYSIS; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PERFUSION; CALCIUM CELL LEVEL; CELL DEATH; CEREBROVASCULAR ACCIDENT; DRUG DOSE ESCALATION; DRUG MEGADOSE; EXCITOTOXICITY; FELINE MODEL; GENE EXPRESSION; GERBIL MODEL; HEMODILUTION; HUMAN; ISCHEMIC CELL DEATH; LACUNAR STROKE; MEAN ARTERIAL PRESSURE; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTICENTER STUDY (TOPIC); NERVE REGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; THROMBOSIS PREVENTION; TRANSCRIPTION REGULATION; TRAUMATIC BRAIN INJURY;

EID: 84929302391     PISSN: None     EISSN: 20763425     Source Type: Journal    
DOI: 10.3390/brainsci3031325     Document Type: Review

References (188)

1. Katsura, K.; Suda, S.; Abe, A.; Kanamaru, T.; Toda, Y.; Katayama, Y. Brain protection therapy in acute cerebral infarction. J. Nippon Med. Sch. 2012, 79, 104-110.
2. Sutherland, B.A.; Minnerup, J.; Balami, J.S.; Arba, F.; Buchan, A.M.; Kleinschnitz, C. Neuroprotection for ischaemic stroke: Translation from the bench to the bedside. Int. J. Stroke 2012, 7,407-418.
3. Widgerow, A.D. Ischemia-reperfusion injury: Influencing the microcirculatory and cellular environment. i4ww. Plast. Surg. 2012, doi:10.1097/SAP.0b013e31825c089c.
4. Durukan, A.; Tatlisumak, T. Acute ischemic stroke: Overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol. Biochem. Behav. 2007, 57, 179-197.
5. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis. 2003, 75, 222-229.
6. Shinohara, Y.; Saito, I.; Kobayashi, S.; Uchiyama, S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (edo trial). Cerebrovasc. Dis. 2009, 27, 485-492.
7. Watanabe, T.; Tanaka, M.; Watanabe, K.; Takamatsu, Y.; Tobe, A. Research and development of the free radical scavenger edaravone as a neuroprotectant. Yakugaku Zasshi 2004, 124, 99-111.
8. Higashi, Y.; Jitsuiki, D.; Chayama, K.; Yoshizumi, M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discov. 2006, 1, 85-93.
9. Yoshida, H.; Yanai, H.; Namiki, Y.; Fukatsu-Sasaki, K.; Furutani, N.; Tada, N. Neuroprotective effects of edaravone: A novel free radical scavenger in cerebrovascular injury. CNS Drug Rev. 2006, 12, 9-20.
10. Lees, K.R.; Zivin, J.A.; Ashwood, T.; Davalos, A.; Davis, S.M.; Diener, H.C.; Grotta, J.; Lyden, P.; Shuaib, A.; Hardemark, H.G. et al. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 2006, 354, 588-600.
11. Lees, K.R.; Davalos, A.; Davis, S.M.; Diener, H.C.; Grotta, J.; Lyden, P.; Shuaib, A.; Ashwood, T.; Hardemark, H.G.; Wasiewski, W. et al. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the saint i trial. Stroke 2006, 37, 2970-2978.
12. Tirilazad international steering committee. Tirilazad mesylate in acute ischemic stroke: A systematic review. Stroke 2000, 31, 2257-2265.
13. Goto, F.; Takakura, K.; Shinohara, Y. Usefulness of avs (nicaraven) for acute stage of cerebrovascular disorder. Studies by multi-institutional double blind test. Rinsyo Kenkyu 1989, 66, 3577-3596.
14. Sakai, F.; Goto, F.; Takakura, K. Kyuu-seiki nou syukketsu nou kousoku kanjya ni taisuru nicaraven no shiteki youryou no kentou. Kouki dai II sou nijyuu mouken shiken (in Japanese). Igaku No Ayumi 1995, 175, 767-798.
15. Minnerup, J.; Sutherland, B.A.; Buchan, A.M.; Kleinschnitz, C. Neuroprotection for stroke: Current status and future perspectives. Int. J. Mol. Sci. 2012, 13, 11753-11772.
16. Yamaguchi, T.; Sano, K.; Takakura, K.; Saito, I.; Shinohara, Y.; Asano, T.; Yasuhara, H. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. Ebselen study group. Stroke 1998, 29, 12-17.
17. Yamaguchi, T. Stroke Trials Registry Home Page. Avaiable online: http://www.strokecenter.org/trials/clinicalstudies/list?utf8=%E2%9C%93&filters[name_or_brief summary_or_detailed_description_or_acronym_contains]=Ebselen&filters[overall_status_name_equals]=&filters[phase_equals]=&filters[clinicalstudies_registries_registry_id_equals]=&filters[conditions_id_equals_any]=&filters[interventions_id_equals_any]=&filters[studydesigns_allocation_equals]=&filters[studydesigns_primary_purpose_equals]=&filters[studydesigns_time_perspective_equals]=&filters[studydesigns_intervention_model_equals]=&filters[studydesigns_masking_equals]=&filters[studydesigns_observational_model_equals]=&filters[studydesigns_endpoin t_classification_equals]=&filters[gender_equals]=&filters[results_available_equals]=0 (accessed on 28 January 2013).
18. Akane, M.; Shimazawa, M.; Inokuchi, Y.; Tsuruma, K.; Hara, H. SUN N8075, a novel radical scavenger, protects against retinal cell death in mice. Neurosci. Lett. 2011, 488, 87-91.
19. Gelmers, H.J.; Gorter, K.; de Weerdt, C.J.; Wiezer, H.J. A controlled trial of nimodipine in acute ischemic stroke. N. Engl. J. Med. 1988, 318, 203-207.
20. Gelmers, H.J.; Hennerici, M. Effect of nimodipine on acute ischemic stroke. Pooled results from five randomized trials. Stroke 1990, 21, IV81-IV84.
21. Horn, J.; Limburg, M. Calcium antagonists for ischemic stroke: A systematic review. Stroke 2001, 32, 570-576.
22. Candelise, L.; Ciccone, A. Gangliosides for acute ischemic stroke. Stroke 2002, 33, 2336.
23. Ricci, S.; Celani, M.G.; Cantisani, T.A.; Righetti, E. Piracetam for acute ischaemic stroke. Cochrane Database Syst. Rev. 2012, doi:10.1002/14651858.CD000419.pub3.
24. Katsura, K.; Katayama, Y. Kyoketsusei shinkei saiboushi no bunshi kikou to nou hogo ryouhou. Shinki nou hogoyaku he no kitai (in Japanese). Nou Jyunkan Taisya 2006, 18, 73-77.
25. Davis, S.M.; Lees, K.R.; Albers, G.W.; Diener, H.C.; Markabi, S.; Karlsson, G.; Norris, J. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke 2000, 31, 347-354.
26. Muir, K.W.; Lees, K.R. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst. Rev. 2003, doi:10.1002/14651858.CD001244.
27. Lees, K.R.; Asplund, K.; Carolei, A.; Davis, S.M.; Diener, H.C.; Kaste, M.; Orgogozo, J.M.; Whitehead, J. Glycine antagonist (gavestinel) in neuroprotection (GAIN international) in patients withacute stroke: A randomised controlled trial. GAIN international investigators. Lancet 2000, 355, 1949-1954.
28. Sacco, R.L.; DeRosa, J.T.; Haley, E.C.; Levin, B.; Ordronneau, P.; Phillips, S.J.; Rundek, T.; Snipes, R.G.; Thompson, J.L. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: A randomized controlled trial. JAMA 2001, 285, 1719-1728.
29. Singh, H.; Jalodia, S.; Gupta, M.S.; Talapatra, P.; Gupta, V.; Singh, I. Role of magnesium sulfate in neuroprotection in acute ischemic stroke. Ann. Indian Acad. Neurol. 2012, 15, 177-180.
30. Muir, K.W.; Lees, K.R.; Ford, I.; Davis, S. Magnesium for acute stroke (intravenous magnesium efficacy in stroke trial): Randomised controlled trial. Lancet 2004, 363, 439-445.
31. Lyden, P.; Shuaib, A.; Ng, K.; Levin, K.; Atkinson, R.P.; Rajput, A.; Wechsler, L.; Ashwood, T.; Claesson, L.; Odergren, T. et al. Clomethiazole acute stroke study in ischemic stroke (CLASS-I): Final results. Stroke 2002, 33, 122-128.
32. Wahlgren, N.G.; Ranasinha, K.W.; Rosolacci, T.; Franke, C.L.; van Erven, P.M.; Ashwood, T.; Claesson, L. Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke 1999, 30, 21-28.
33. Diener, H.C. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and australian lubeluzole ischaemic stroke study group. Cerebrovasc. Dis. 1998, 8, 172-181.
34. Grotta, J. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke 1997, 28, 2338-2346.
35. Diener, H.C.; Cortens, M.; Ford, G.; Grotta, J.; Hacke, W.; Kaste, M.; Koudstaal, P.J.; Wessel, T. Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 2000, 31, 2543-2551.
36. Gandolfo, C.; Sandercock, P.; Conti, M. Lubeluzole for acute ischaemic stroke. Cochrane Database Syst. Rev. 2002, doi:10.1002/14651858.CD001924.
37. Clark, W.M.; Raps, E.C.; Tong, D.C.; Kelly, R.E. Cervene (Nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke 2000, 31, 1234-1239.
38. Zweifler, R.M. Membrane stabilizer: Citicoline. Curr. Med. Res. Opin. 2002, 18, s14-s17.
39. Davalos, A.; Alvarez-Sabin, J.; Castillo, J.; Diez-Tejedor, E.; Ferro, J.; Martinez-Vila, E.; Serena, J.; Segura, T.; Cruz, V.T.; Masjuan, J. et al. Citicoline in the treatment of acute ischaemic stroke: An international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012, 380, 349-357.
40. Clark, W.M.; Williams, B.J.; Selzer, K.A.; Zweifler, R.M.; Sabounjian, L.A.; Gammans, R.E. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999, 30, 2592-2597.
41. Tazaki, Y.; Sakai, F.; Otomo, E.; Kutsuzawa, T.; Kameyama, M.; Omae, T.; Fujishima, M.; Sakuma, A. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988, 19, 211-216.
42. Clark, W.M.; Wechsler, L.R.; Sabounjian, L.A.; Schwiderski, U.E. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001, 57, 1595-1602.
43. Diener, H.C.; Schneider, D.; Lampl, Y.; Bornstein, N.M.; Kozak, A.; Rosenberg, G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke 2008, 39, 1774-1778.
44. Rosenberg, G.; Bornstein, N.; Diener, H.C.; Gorelick, P.B.; Shuaib, A.; Lees, K. The membrane-activated chelator stroke intervention (macsi) trial of DP-b99 in acute ischemic stroke: A randomized, double-blind, placebo-controlled, multinational pivotal phase III study. Int. J. Stroke 2011, 6, 362-367.
45. Jain, K. The Handbook of Neuroprotection; Humana Press: New York, NY, USA, 2011.
46. Ringelstein, B.; Thjis, V.; Chamorro, A.; Grond, M.; Saver, J.; Norrving, B.; Aichner, F. New Drug Doesn't Improve Disability among Stroke Patients. Avaiable online: http://newsroom.heart.org/news/new-drug-doesn-t-improve-disability-228205 (accessed on 28 January 2013).
47. Prajapati, K.D.; Sharma, S.S.; Roy, N. Current perspectives on potential role of albumin in neuroprotection. Rev. Neurosci. 2011, 22, 355-363.
48. Ginsberg, M.D.; Hill, M.D.; Palesch, Y.Y.; Ryckborst, K.J.; Tamariz, D. The alias pilot trial: A dose-escalation and safety study of albumin therapy for acute ischemic stroke-I: Physiological responses and safety results. Stroke 2006, 37, 2100-2106.
49. Palesch, Y.Y.; Hill, M.D.; Ryckborst, K.J.; Tamariz, D.; Ginsberg, M.D. The alias pilot trial: A dose-escalation and safety study of albumin therapy for acute ischemic stroke-II: Neurologic outcome and efficacy analysis. Stroke 2006, 37, 2107-2114.
50. Ginsberg, M.D.; Palesch, Y.Y.; Martin, R.H.; Hill, M.D.; Moy, C.S.; Waldman, B.D.; Yeatts, S.D.; Tamariz, D.; Ryckborst, K.; Investigators, A. The albumin in acute stroke (ALIAS) multicenter clinical trial: Safety analysis of part 1 and rationale and design of part 2. Stroke 2011, 42, 119-127.
51. Hill, M.D.; Martin, R.H.; Palesch, Y.Y.; Tamariz, D.; Waldman, B.D.; Ryckborst, K.J.; Moy, C.S.; Barsan, W.G.; Ginsberg, M.D.; Investigators, A.; et al. The albumin in acute stroke part 1 trial: An exploratory efficacy analysis. Stroke 2011, 42, 1621-1625.
52. Tateishi, N.; Mori, T.; Kagamiishi, Y.; Satoh, S.; Katsube, N.; Morikawa, E.; Morimoto, T.; Matsui, T.; Asano, T. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: Suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J. Cereb. Blood Flow Metab. 2002, 22, 723-734.
53. Ono Pharmaceutical Co. Ltd. Announcement on Results of Phase II/III Clinical Study in Japan with Arocyte for Injection for Treatment of Acute Ischemic Stroke. http://www.ono.co.jp/eng/news/pdf/sm_cn081001.pdf (accessed on 28 January 2013).
54. Kamei, K.; Maeda, N.; Ogino, R.; Koyama, M.; Nakajima, M.; Tatsuoka, T.; Ohno, T.; Inoue, T. New 5-HT1A receptor agonists possessing 1,4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects. Bioorg. Med. Chem. Lett. 2001, 11, 595-598.
55. Miyata, N.; Roman, R.J. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J. Smooth Muscle Res. 2005, 41, 175-193.
56. Ganong, W.F. Review of Medical Physiology, 22nd ed.; McGraw-Hill: New York, NY, USA, 2003.
57. Liu, J.; Farmer, J.D., Jr.; Lane, W.S.; Friedman, J.; Weissman, I.; Schreiber, S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66, 807-815.
58. Sharkey, J.; Butcher, S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 1994, 371, 336-339.
59. Arii, T.; Kamiya, T.; Arii, K.; Ueda, M.; Nito, C.; Katsura, K.I.; Katayama, Y. Neuroprotective effect of immunosuppressant FK506 in transient focal ischemia in rat: Therapeutic time window for FK506 in transient focal ischemia. Neurol. Res. 2001, 23, 755-760.
60. Katsura, K.; Kurihara, J.; Hiraide, T.; Takahashi, K.; Kato, H.; Katayama, Y. Effects of FK506 on the translocation of protein kinase C and CaM kinase Ii in the gerbil hippocampal CA1 neurons. Neurol. Res. 2003, 25, 522-527.
61. Katsura, K.; Takahashi, K.; Asoh, S.; Watanabe, M.; Sakurazawa, M.; Ohsawa, I.; Mori, T.; Igarashi, H.; Ohkubo, S.; Katayama, Y. et al. Combination therapy with transductive anti-death FNK protein and FK506 ameliorates brain damage with focal transient ischemia in rat. J. Neurochem. 2008, 106, 258-270.
62. Gold, B.G. Fk506 and the role of immunophilins in nerve regeneration. Mol. Neurobiol. 1997, 15, 285-306.
63. Steiner, J.P.; Connolly, M.A.; Valentine, H.L.; Hamilton, G.S.; Dawson, T.M.; Hester, L.; Snyder, S.H. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat. Med. 1997, 3, 421-428.
64. Furuichi, Y.; Noto, T.; Li, J.Y.; Oku, T.; Ishiye, M.; Moriguchi, A.; Aramori, I.; Matsuoka, N.; Mutoh, S.; Yanagihara, T. Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats. Brain Res. 2004, 1014, 120-130.
65. 2+-induced apoptosis through calcineurin dephosphorylation of bad. Science 1999, 284, 339-343.
66. Yousuf, S.; Atif, F.; Kesherwani, V.; Agrawal, S.K. Neuroprotective effects of tacrolimus (FK-506) and cyclosporin (CSA) in oxidative injury. Brain Behav. 2011, 1, 87-94.
67. Zawadzka, M.; Kaminska, B. A novel mechanism of FK506-mediated neuroprotection: Downregulation of cytokine expression in glial cells. Glia 2005, 49, 36-51.
68. Gold, B.G.; Voda, J.; Yu, X.; McKeon, G.; Bourdette, D.N. FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: Neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis. J. Neurosci. Res. 2004, 77, 367-377.
69. Laupacis, A.; Keown, P.A.; Ulan, R.A.; McKenzie, N.; Stiller, C.R. Cyclosporin A: A powerful immunosuppressant. Can. Med. Assoc. J. 1982, 126, 1041-1046.
70. Li, P.A.; Uchino, H.; Elmer, E.; Siesjo, B.K. Amelioration by cyclosporin A of brain damage following 5 or 10 min of ischemia in rats subjected to preischemic hyperglycemia. Brain Res. 1997, 753, 133-140.
71. Uchino, H.; Elmer, E.; Uchino, K.; Lindvall, O.; Siesjo, B.K. Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat. Acta Physiol. Scand. 1995, 155, 469-471.
72. Uchino, H.; Elmer, E.; Uchino, K.; Li, P.A.; He, Q.P.; Smith, M.L.; Siesjo, B.K. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat. Brain Res. 1998, 812, 216-226.
73. Mirzayan, M.J.; Klinge, P.M.; Ude, S.; Hotop, A.; Samii, M.; Brinker, T.; Korkmaz, Z.; Meyer, G.J.; Knapp, W.H.; Samii, A. Modified calcium accumulation after controlled cortical impact under cyclosporin A treatment: A 45Ca autoradiographic study. Neurol. Res. 2008, 30, 476-479.
74. Tsujimoto, Y.; Shimizu, S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 2007, 12, 835-840.
75. Mbye, L.H.; Singh, I.N.; Carrico, K.M.; Saatman, K.E.; Hall, E.D. Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J. Cereb. Blood Flow Metab. 2009, 29, 87-97.
76. Signoretti, S.; Marmarou, A.; Tavazzi, B.; Dunbar, J.; Amorini, A.M.; Lazzarino, G.; Vagnozzi, R. The protective effect of cyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following experimental diffuse traumatic brain injury. J. Neurotrauma 2004, 21, 1154-1167.
77. Van Den Heuvel, C.; Donkin, J.J.; Finnie, J.W.; Blumbergs, P.C.; Kuchel, T.; Koszyca, B.; Manavis, J.; Jones, N.R.; Reilly, P.L.; Vink, R. Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration. J. Neurotrauma 2004, 21, 1562-1572.
78. Okonkwo, D.O.; Melon, D.E.; Pellicane, A.J.; Mutlu, L.K.; Rubin, D.G.; Stone, J.R.; Helm, G.A. Dose-response of cyclosporin A in attenuating traumatic axonal injury in rat. Neuroreport 2003, 14, 463-466.
79. Mazzeo, A.T.; Beat, A.; Singh, A.; Bullock, M.R. The role of mitochondrial transition pore, and its modulation, in traumatic brain injury and delayed neurodegeneration after TBI. Exp. Neurol. 2009, 218, 363-370.
80. Hatton, J.; Rosbolt, B.; Empey, P.; Kryscio, R.; Young, B. Dosing and safety of cyclosporine in patients with severe brain injury. J. Neurosurg. 2008, 109, 699-707.
81. Mazzeo, A.T.; Alves, O.L.; Gilman, C.B.; Hayes, R.L.; Tolias, C.; Niki Kunene, K.; Ross Bullock, M. Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: A microdialysis study. Acta Neurochir. 2008, 150, 1019-1031; discussion 1031.
82. Nighoghossian, N. Neuroprotection Impact of Cyclosporin A in Cerebral Infarction (Csastroke). Available online: http://clinicaltrials.gov/show/NCT01527240 (accessed on 28 January 2013).
83. Cho, B.B.; Toledo-Pereyra, L.H. Caspase-independent programmed cell death following ischemic stroke. J. Invest. Surg. 2008, 21, 141-147.
84. Yakel, J.L. Calcineurin regulation of synaptic function: From ion channels to transmitter release and gene transcription. Trends Pharmacol. Sci. 1997, 18, 124-134.
85. Morioka, M.; Hamada, J.; Ushio, Y.; Miyamoto, E. Potential role of calcineurin for brain ischemia and traumatic injury. Prog. Neurobiol. 1999, 58, 1-30.
86. Clemens, J.A. Cerebral ischemia: Gene activation, neuronal injury, and the protective role of antioxidants. Free Radic. Biol. Med. 2000, 28, 1526-1531.
87. Shibasaki, F.; Kondo, E.; Akagi, T.; McKeon, F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997, 386, 728-731.
88. Uchino, H.; Kuroda, Y.; Morota, S.; Hirabayashi, G.; Ishii, N.; Shibasaki, F.; Ikeda, Y.; Hansson, M.J.; Elmer, E. Probing the molecular mechanisms of neuronal degeneration: Importance of mitochondrial dysfunction and calcineurin activation. J. Anesth. 2008, 22, 253-262.
89. Yoshimoto, T.; Uchino, H.; He, Q.P.; Li, P.A.; Siesjo, B.K. Cyclosporin A, but not FK506, prevents the downregulation of phosphorylated Akt after transient focal ischemia in the rat. Brain Res. 2001, 899, 148-158.
90. Wang, X.; Carlsson, Y.; Basso, E.; Zhu, C.; Rousset, C.I.; Rasola, A.; Johansson, B.R.; Blomgren, K.; Mallard, C.; Bernardi, P. et al. Developmental shift of cyclophilin D contribution to hypoxic-ischemic brain injury. J. Neurosci. 2009, 29, 2588-2596.
91. Hubble, J.P. Pre-clinical studies of pramipexole: Clinical relevance. Eur. J. Neurol. 2000, 7, 15-20.
92. Abramova, N.A.; Cassarino, D.S.; Khan, S.M.; Painter, T.W.; Bennett, J.P., Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J. Neurosci. Res. 2002, 67, 494-500.
93. Danzeisen, R.; Schwalenstoecker, B.; Gillardon, F.; Buerger, E.; Krzykalla, V.; Klinder, K.; Schild, L.; Hengerer, B.; Ludolph, A.C.; Dorner-Ciossek, C.; Kussmaul, L. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J. Pharmacol. Exp. Ther. 2006, 316, 189-199.
94. Sayeed, I.; Parvez, S.; Winkler-Stuck, K.; Seitz, G.; Trieu, I.; Wallesch, C.W.; Schönfeld, P.; Siemen, D. Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. FASEB J. 2006, 20, 556-558.
95. Ferrari-Toninelli, G.; Maccarinelli, G.; Uberti, D.; Buerger, E.; Memo, M. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol. 2010, 10, doi:10.1186/1471-2210-10-2.
96. Settaf, A.; Zahidy, M.; Elimadi, A.; Sapena, R.; Alsamad, I.A.; Tillement, J.; Morin, D. S-15176 reduces the hepatic injury in rats subjected to experimental ischemia and reperfusion. Eur. J. Pharmacol. 2000, 406, 281-292.
97. Rupp, H.; Zarain-Herzberg, A.; Maisch, B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002, 27, 621-636.
98. Elimadi, A.; Jullien, V.; Tillement, J.P.; Morin, D. S-15176 inhibits mitochondrial permeability transition via a mechanism independent of its antioxidant properties. Eur. J. Pharmacol. 2003, 468, 93-101.
99. Miyata, K.; Omori, N.; Uchino, H.; Yamaguchi, T.; Isshiki, A.; Shibasaki, F. Involvement of the brain-derived neurotrophic factor/TrkB pathway in neuroprotecive effect of cyclosporin A in forebrain ischemia. Neuroscience 2001, 105, 571-578.
100. Kawakami, M.; Yoshimoto, T.; Nakagata, N.; Yamamura, K.; Siesjo, B.K. Effects of cyclosporin A administration on gene expression in rat brain. Brain Inj. 2011, 25, 614-623.
101. Diatchenko, L.; Lau, Y.F.; Campbell, A.P.; Chenchik, A.; Moqadam, F.; Huang, B.; Lukyanov, S.; Lukyanov, K.; Gurskaya, N.; Sverdlov, E.D. et al. Suppression subtractive hybridization: A method for generating differentially regulated or tissue-specific cdna probes and libraries. Proc. Natl. Acad. Sci. USA 1996, 93, 6025-6030.
102. Mathur, S.; Cleary, K.R.; Inamdar, N.; Kim, Y.H.; Steck, P.; Frazier, M.L. Overexpression of elongation factor-1gamma protein in colorectal carcinoma. Cancer 1998, 82, 816-821.
103. Cavallius, J.; Rattan, S.I.; Clark, B.F. Changes in activity and amount of active elongation factor 1 alpha in aging and immortal human fibroblast cultures. Exp. Gerontol. 1986, 21, 149-157.
104. Shepherd, J.C.; Walldorf, U.; Hug, P.; Gehring, W.J. Fruit flies with additional expression of the elongation factor EF-1 alpha live longer. Proc. Natl. Acad. Sci. USA 1989, 86, 7520-7521.
105. Wang, J.F.; Engelsberg, B.N.; Johnson, S.W.; Witmer, C.; Merrick, W.C.; Rozmiarek, H.; Billings, P.C. DNA binding activity of the mammalian translation elongation complex: Recognition of chromium- and transplatin-damaged DNA. Arch. Toxicol. 1997, 71, 450-454.
106. Jung, M.; Kondratyev, A.D.; Dritschilo, A. Elongation factor 1 delta is enhanced following exposure to ionizing radiation. Cancer Res. 1994, 54, 2541-2543.
107. DeWille, J.W.; Farmer, S.J. Quaking phenotype influences brain lipid-related mRNA levels. Neurosci. Lett. 1992, 141, 195-198.
108. DeWille, J.W.; Farmer, S.J. Postnatal dietary fat influences mRNAs involved in myelination. Dev. Neurosci. 1992, 14, 61-68.
109. Zumkeller, W. The effect of insulin-like growth factors on brain myelination and their potential therapeutic application in myelination disorders. Eur. J. Paediatr. Neurol. 1997, 1, 91-101.
110. Kubota, H.; Yokota, S.; Yanagi, H.; Yura, T. Structures and co-regulated expression of the genes encoding mouse cytosolic chaperonin CCT subunits. Eur. J. Biochem. 1999, 262, 492-500.
111. Stoldt, V.; Rademacher, F.; Kehren, V.; Ernst, J.F.; Pearce, D.A.; Sherman, F. Review: The CCT eukaryotic chaperonin subunits of saccharomyces cerevisiae and other yeasts. Yeast 1996, 12, 523-529.
112. Creutz, C.E.; Liou, A.; Snyder, S.L.; Brownawell, A.; Willison, K. Identification of the major chromaffin granule-binding protein, chromobindin A, as the cytosolic chaperonin CCT (chaperonin containing TCP-1). J. Biol. Chem. 1994, 269, 32035-32038.
113. Roobol, A.; Holmes, F.E.; Hayes, N.V.; Baines, A.J.; Carden, M.J. Cytoplasmic chaperonin complexes enter neurites developing in vitro and differ in subunit composition within single cells. J. Cell Sci. 1995, 108, 1477-1488.
114. Bloom, L.; Horvitz, H.R. The Caenorhabditis elegans gene unc-76 and its human homologs define a new gene family involved in axonal outgrowth and fasciculation. Proc. Natl. Acad. Sci. USA 1997, 94, 3414-3419.
115. Kuroda, S.; Nakagawa, N.; Tokunaga, C.; Tatematsu, K.; Tanizawa, K. Mammalian homologue of the Caenorhabditis elegans unc-76 protein involved in axonal outgrowth is a protein kinase C zeta-interacting protein. J. Cell Biol. 1999, 144, 403-411.
116. Aitken, A. 14-3-3 proteins on the map. Trends Biochem. Sci. 1995, 20, 95-97.
117. Zha, J.; Harada, H.; Yang, E.; Jockel, J.; Korsmeyer, S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996, 87, 619-628.
118. Zhang, L.; Chen, J.; Fu, H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc. Natl. Acad. Sci. USA 1999, 96, 8511-8515.
119. Hara, H.; Friedlander, R.M.; Gagliardini, V.; Ayata, C.; Fink, K.; Huang, Z.; Shimizu-Sasamata, M.; Yuan, J.; Moskowitz, M.A. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl. Acad. Sci. USA 1997, 94, 2007-2012.
120. Yaoita, H.; Ogawa, K.; Maehara, K.; Maruyama, Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998, 97, 276-281.
121. Cheng, Y.; Deshmukh, M.; D'Costa, A.; Demaro, J.A.; Gidday, J.M.; Shah, A.; Sun, Y.; Jacquin, M.F.; Johnson, E.M.; Holtzman, D.M. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J. Clin. Invest. 1998, 101, 1992-1999.
122. Chen, J.; Nagayama, T.; Jin, K.; Stetler, R.A.; Zhu, R.L.; Graham, S.H.; Simon, R.P. Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia. J. Neurosci. 1998, 18, 4914-4928.
123. Rabuffetti, M.; Sciorati, C.; Tarozzo, G.; Clementi, E.; Manfredi, A.A.; Beltramo, M. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J. Neurosci. 2000, 20, 4398-4404.
124. Martinou, J.C.; Dubois-Dauphin, M.; Staple, J.K.; Rodriguez, I.; Frankowski, H.; Missotten, M.; Albertini, P.; Talabot, D.; Catsicas, S.; Pietra, C. et al. Overexpression of Bcl-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 1994, 13, 1017-1030.
125. Wiessner, C.; Allegrini, P.R.; Rupalla, K.; Sauer, D.; Oltersdorf, T.; McGregor, A.L.; Bischoff, S.; Bottiger, B.W.; van der Putten, H. Neuron-specific transgene expression of Bcl-XL but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice. Neurosci. Lett. 1999, 268, 119-122.
126. Xing, H.; Zhang, S.; Weinheimer, C.; Kovacs, A.; Muslin, A.J. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J. 2000, 19, 349-358.
127. Landgraf, P.; Wahle, P.; Pape, H.C.; Gundelfinger, E.D.; Kreutz, M.R. The survival-promoting peptide Y-P30 enhances binding of pleiotrophin to syndecan-2 and -3 and supports its neuritogenic activity. J. Biol. Chem. 2008, 283, 25036-25045.
128. Landgraf, P.; Sieg, F.; Wahle, P.; Meyer, G.; Kreutz, M.R.; Pape, H.C. A maternal blood-borne factor promotes survival of the developing thalamus. FASEB J. 2005, 19, 225-227.
129. Zhao, Y.; Lang, G.; Ito, S.; Bonnet, J.; Metzger, E.; Sawatsubashi, S.; Suzuki, E.; Le Guezennec, X.; Stunnenberg, H.G.; Krasnov, A. et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol. Cell 2008, 29, 92-101.
130. Nagy, Z.; Tora, L. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 2007, 26, 5341-5357.
131. Leng, N.; Gu, G.; Simerly, R.B.; Spindel, E.R. Molecular cloning and characterization of two putative g protein-coupled receptors which are highly expressed in the central nervous system. Brain Res. Mol. Brain Res. 1999, 69, 73-83.
132. Marazziti, D.; Gallo, A.; Golini, E.; Matteoni, R.; Tocchini-Valentini, G.P. Molecular cloning and chromosomal localization of the mouse Gpr37 gene encoding an orphan G-protein-coupled peptide receptor expressed in brain and testis. Genomics 1998, 53, 315-324.
133. Rezgaoui, M.; Susens, U.; Ignatov, A.; Gelderblom, M.; Glassmeier, G.; Franke, I.; Urny, J.; Imai, Y.; Takahashi, R.; Schaller, H.C. The neuropeptide head activator is a high-affinity ligand for the orphan G-protein-coupled receptor Gpr37. J. Cell Sci. 2006, 119, 542-549.
134. Bodenmuller, H.; Schaller, H.C. Conserved amino acid sequence of a neuropeptide, the head activator, from coelenterates to humans. Nature 1981, 293, 579-580.
135. Berman, S.B.; Hastings, T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for parkinson's disease. J. Neurochem. 1999, 73, 1127-1137.
136. Famulski, J.K.; Vos, L.; Sun, X.; Chan, G. Stable hZW10 kinetochore residency, mediated by hZwint-1 interaction, is essential for the mitotic checkpoint. J. Cell Biol. 2008, 180, 507-520.
137. Van Vlijmen, T.; Vleugel, M.; Evers, M.; Mohammed, S.; Wulf, P.S.; Heck, A.J.; Hoogenraad, C.C.; van der Sluijs, P. A unique residue in rab3c determines the interaction with novel binding protein Zwint-1. FEBS Lett. 2008, 582, 2838-2842.
138. Rogers, J.; Cooper, N.R.; Webster, S.; Schultz, J.; McGeer, P.L.; Styren, S.D.; Civin, W.H.; Brachova, L.; Bradt, B.; Ward, P. et al. Complement activation by beta-amyloid in alzheimer disease. Proc. Natl. Acad. Sci. USA 1992, 89, 10016-10020.
139. Jiang, H.; Burdick, D.; Glabe, C.G.; Cotman, C.W.; Tenner, A.J. Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q a chain. J. Immunol. 1994, 152, 5050-5059.
140. Afagh, A.; Cummings, B.J.; Cribbs, D.H.; Cotman, C.W.; Tenner, A.J. Localization and cell association of C1q in Alzheimer's disease brain. Exp. Neurol. 1996, 138, 22-32.
141. Yao, J.; Harvath, L.; Gilbert, D.L.; Colton, C.A. Chemotaxis by a CNS macrophage, the microglia. J. Neurosci. Res. 1990, 27, 36-42.
142. O'Barr, S.; Cooper, N.R. The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: Implications for Alzheimer's disease. J. Neuroimmunol. 2000, 109, 87-94.
143. Benveniste, E.N.; Nguyen, V.T.; O'Keefe, G.M. Immunological aspects of microglia: Relevance to Alzheimer's disease. Neurochem. Int. 2001, 39, 381-391.
144. Tenner, A.J. Complement in Alzheimer's disease: Opportunities for modulating protective and pathogenic events. Neurobiol. Aging 2001, 22, 849-861.
145. Fonseca, M.I.; Zhou, J.; Botto, M.; Tenner, A.J. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 2004, 24, 6457-6465.
146. Pedersen, E.D.; Waje-Andreassen, U.; Vedeler, C.A.; Aamodt, G.; Mollnes, T.E. Systemic complement activation following human acute ischaemic stroke. Clin. Exp. Immunol. 2004, 137, 117-122.
147. Arumugam, T.V.; Magnus, T.; Woodruff, T.M.; Proctor, L.M.; Shiels, I.A.; Taylor, S.M. Complement mediators in ischemia-reperfusion injury. Clin. Chim. Acta 2006, 374, 33-45.
148. Ten, V.S.; Sosunov, S.A.; Mazer, S.P.; Stark, R.I.; Caspersen, C.; Sughrue, M.E.; Botto, M.; Connolly, E.S.,; Pinsky, D.J. C1q-deficiency is neuroprotective against hypoxic-ischemic brain injury in neonatal mice. Stroke 2005, 36, 2244-2250.
149. Ten, V.S.; Yao, J.; Ratner, V.; Sosunov, S.; Fraser, D.A.; Botto, M.; Sivasankar, B.; Morgan, B.P.; Silverstein, S.; Stark, R. et al. Complement component C1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. J. Neurosci. 2010, 30, 2077-2087.
150. Girod, A.; Storrie, B.; Simpson, J.C.; Johannes, L.; Goud, B.; Roberts, L.M.; Lord, J.M.; Nilsson, T.; Pepperkok, R. Evidence for a COP-I-independent transport route from the Golgi complex to the endoplasmic reticulum. Nat. Cell Biol. 1999, 1, 423-430.
151. White, J.; Johannes, L.; Mallard, F.; Girod, A.; Grill, S.; Reinsch, S.; Keller, P.; Tzschaschel, B.; Echard, A.; Goud, B. et al. Rab6 coordinates a novel Golgi to er retrograde transport pathway in live cells. J. Cell Biol. 1999, 147, 743-760.
152. McConlogue, L.; Castellano, F.; deWit, C.; Schenk, D.; Maltese, W.A. Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta-amyloid precursor protein. J. Biol. Chem. 1996, 271, 1343-1348.
153. Scheper, W.; Hoozemans, J.J.; Hoogenraad, C.C.; Rozemuller, A.J.; Eikelenboom, P.; Baas, F. Rab6 is increased in Alzheimer's disease brain and correlates with endoplasmic reticulum stress. Neuropathol. Appl. Neurobiol. 2007, 33, 523-532.
154. Lin, L.; Jeanclos, E.M.; Treuil, M.; Braunewell, K.H.; Gundelfinger, E.D.; Anand, R. The calcium sensor protein visinin-like protein-1 modulates the surface expression and agonist sensitivity of the alpha 4beta 2 nicotinic acetylcholine receptor. J. Biol. Chem. 2002, 277, 41872-41878.
155. Schnurra, I.; Bernstein, H.G.; Riederer, P.; Braunewell, K.H. The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: A link between calcium sensors and Alzheimer's disease? Neurobiol. Dis. 2001, 8, 900-909.
156. Mali, Y.; Zisapels, N. Gain of interaction of ALS-linked G93A superoxide dismutase with cytosolic malate dehydrogenase. Neurobiol. Dis. 2008, 32, 133-141.
157. Volkert, M.R.; Elliott, N.A.; Housman, D.E. Functional genomics reveals a family of eukaryotic oxidation protection genes. Proc. Natl. Acad. Sci. USA 2000, 97, 14530-14535.
158. Natoli, R.; Provis, J.; Valter, K.; Stone, J. Expression and role of the early-response gene Oxr1 in the hyperoxia-challenged mouse retina. Invest. Ophthalmol. Vis. Sci. 2008, 49, 4561-4567.
159. Inouye, S.; Seo, M.; Yamada, Y.; Nakazawa, A. Increase of adenylate kinase isozyme 1 protein during neuronal differentiation in mouse embryonal carcinoma p19 cells and in rat brain primary cultured cells. J. Neurochem. 1998, 71, 125-133.
160. O'Rourke, J.F.; Pugh, C.W.; Bartlett, S.M.; Ratcliffe, P.J. Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur. J. Biochem. 1996, 241, 403-410.
161. Shahjahan, M.; Yamada, M.; Tanaka, H.; Nakazawa, A. Cloning and characterization of the gene encoding bovine mitochondrial adenylate kinase isozyme 3. Gene 1991, 107, 313-317.
162. Popanda, O.; Fox, G.; Thielmann, H.W. Modulation of DNA polymerases alpha, delta and epsilon by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim. Biophys. Acta 1998, 1397, 102-117.
163. Ogino, T.; Iwama, M.; Kinouchi, J.; Shibagaki, Y.; Tsukamoto, T.; Mizumoto, K. Involvement of a cellular glycolytic enzyme, phosphoglycerate kinase, in sendai virus transcription. J. Biol. Chem. 1999, 274, 35999-36008.
164. Shetty, S.; Muniyappa, H.; Halady, P.K.; Idell, S. Regulation of urokinase receptor expression by phosphoglycerate kinase. Am. J. Respir. Cell Mol. Biol. 2004, 31, 100-106.
165. Lay, A.J.; Jiang, X.M.; Kisker, O.; Flynn, E.; Underwood, A.; Condron, R.; Hogg, P.J. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 2000, 408, 869-873.
166. Gold, B.G.; Gordon, H.S.; Wang, M.S. Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: Lack of evidence for a conditioning lesion-like effect. Neurosci. Lett. 1999, 267, 33-36.
167. Friberg, H.; Ferrand-Drake, M.; Bengtsson, F.; Halestrap, A.P.; Wieloch, T. Cyclosporin A, but not FK506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J. Neurosci. 1998, 18, 5151-5159.
168. Nicolli, A.; Basso, E.; Petronilli, V.; Wenger, R.M.; Bernardi, P. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, and cyclosporin A-sensitive channel. J. Biol. Chem. 1996, 271, 2185-2192.
169. Baumann, G.; Zenke, G.; Wenger, R.; Hiestand, P.; Quesniaux, V.; Andersen, E.; Schreier, M.H. Molecular mechanisms of immunosuppression. J. Autoimmun. 1992, 5, 67-72.
170. Hansson, M.J.; Mattiasson, G.; Mansson, R.; Karlsson, J.; Keep, M.F.; Waldmeier, P.; Ruegg, U.T.; Dumont, J.M.; Besseghir, K.; Elmer, E. The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J. Bioenerg. Biomembr. 2004, 36, 407-413.
171. Tiepolo, T.; Angelin, A.; Palma, E.; Sabatelli, P.; Merlini, L.; Nicolosi, L.; Finetti, F.; Braghetta, P.; Vuagniaux, G.; Dumont, J.M. et al. The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/-myopathic mice. Br. J. Pharmacol. 2009, 157, 1045-1052.
172. Giorgio, V.; Soriano, M.E.; Basso, E.; Bisetto, E.; Lippe, G.; Forte, M.A.; Bernardi, P. Cyclophilin D in mitochondrial pathophysiology. Biochim. Biophys. Acta 2010, 1797, 1113-1118.
173. Theiss, A.L.; Sitaraman, S.V. The role and therapeutic potential of prohibitin in disease. Biochim. Biophys. Acta 2011, 1813, 1137-1143.
174. Altus, M.S.; Wood, C.M.; Stewart, D.A.; Roskams, A.J.; Friedman, V.; Henderson, T.; Owens, G.A.; Danner, D.B.; Jupe, E.R.; Dell'Orco, R.T. et al. Regions of evolutionary conservation between the rat and human prohibitin-encoding genes. Gene 1995, 158, 291-294.
175. Nijtmans, L.G.; de Jong, L.; Artal Sanz, M.; Coates, P.J.; Berden, J.A.; Back, J.W.; Muijsers, A.O.; van der Spek, H.; Grivell, L.A. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J. 2000, 19, 2444-2451.
176. Sharma, A.; Qadri, A. VI polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc. Natl. Acad. Sci. USA 2004, 101, 17492-17497.
177. Rastogi, S.; Joshi, B.; Fusaro, G.; Chellappan, S. Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism. J. Biol. Chem. 2006, 281, 2951-2959.
178. Wang, S.; Fusaro, G.; Padmanabhan, J.; Chellappan, S.P. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 2002, 21, 8388-8396.
179. Sripathi, S.R.; He, W.; Atkinson, C.L.; Smith, J.J.; Liu, Z.; Elledge, B.M.; Jahng, W.J. Mitochondrial-nuclear communication by prohibitin shuttling under oxidative stress. Biochemistry 2011, 50, 8342-8351.
180. Sanchez-Quiles, V.; Santamaria, E.; Segura, V.; Sesma, L.; Prieto, J.; Corrales, F.J. Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: Molecular mechanisms and functional implications. Proteomics 2010, 10, 1609-1620.
181. O'Collins, V.E.; Macleod, M.R.; Donnan, G.A.; Horky, L.L.; van der Worp, B.H.; Howells, D.W. 1,026 experimental treatments in acute stroke. Ann. Neurol. 2006, 59, 467-477.
182. Seaton, T.A.; Cooper, J.M.; Schapira, A.H. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Res. 1998, 809, 12-17.
183. Tatton, W.G.; Chalmers-Redman, R.M. Mitochondria in neurodegenerative apoptosis: An opportunity for therapy? Ann. Neurol. 1998, 44, S134-S141.
184. Cassarino, D.S.; Swerdlow, R.H.; Parks, J.K.; Parker, W.D.,; Bennett, J.P., Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem. Biophys. Res. Commun. 1998, 248, 168-173.
185. Wong, A.; Cortopassi, G. Mtdna mutations confer cellular sensitivity to oxidant stress that is partially rescued by calcium depletion and cyclosporin A. Biochem. Biophys. Res. Commun. 1997, 239, 139-145.
186. Sabatini, D.M.; Lai, M.M.; Snyder, S.H. Neural roles of immunophilins and their ligands. Mol. Neurobiol. 1997, 15, 223-239.
187. Miller, R.G.; Sharma, K.R.; Pavlath, G.K.; Gussoni, E.; Mynhier, M.; Lanctot, A.M.; Greco, C.M.; Steinman, L.; Blau, H.M. Myoblast implantation in duchenne muscular dystrophy: The San Francisco study. Muscle Nerve 1997, 20, 469-478.
188. Sharma, K.R.; Mynhier, M.A.; Miller, R.G. Cyclosporine increases muscular force generation in duchenne muscular dystrophy. Neurology 1993, 43, 527-532.